Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.550
-0.100 (-6.06%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.

The company is headquartered in New York, New York.

Citius Oncology, Inc.
Citius Oncology logo
Country United States
Founded 2021

Contact Details

Address:
420 Lexington Avenue, Suite 2446
New York, New York 10170
United States
Phone 347-627-0058

Stock Details

Ticker Symbol CTOR
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001851484
ISIN Number US17331Y1091
SIC Code 2834

Key Executives

Name Position
Xiaofeng Yuan Chief Executive Officer and Chairman
Dahe Zhang Chief Financial Officer and Executive Director

Latest SEC Filings

Date Type Title
Sep 13, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Sep 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 26, 2024 8-K/A [Amend] Current report
Aug 16, 2024 8-K Current Report
Aug 16, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 13, 2024 25-NSE Filing
Aug 9, 2024 10-Q Quarterly Report
Aug 5, 2024 8-K Current Report